Report Highlights

U.S. RNA-Based Therapeutics: Market Overview

The U.S. RNA-based therapeutics market, spanning mRNA therapeutics, small interfering RNA (siRNA), antisense oligonucleotides (ASOs) and exon-skipping agents, was valued at USD 14.6 billion in 2024. SiRNA and ASO products reach patients through New Drug Applications reviewed by the FDA's Center for Drug Evaluation and Research, while mRNA products are licensed as biologics by the Center for Biologics Evaluation and Research under Section 351 of the Public Health Service Act. Government has dominated foundational platform research, while private capital leads commercialization.

Policy has shaped the market in two distinct ways. Operation Warp Speed, launched in 2020 by HHS and the Department of Defense, funded mRNA platform scale-up through BARDA, while the Orphan Drug Act of 1983 steered siRNA sponsors toward rare diseases such as transthyretin-mediated amyloidosis. Alnylam's Onpattro (patisiran), approved in 2018, and Amvuttra (vutrisiran) established commercial precedents under that incentive structure, while Moderna, Alnylam and Ionis now fund most late-stage programs privately.

Policy-Driven Growth in U.S. RNA-Based Therapeutics

The Orphan Drug Act of 1983 provides a 25 percent tax credit under Internal Revenue Code Section 45C on qualified clinical testing expenses and grants seven years of market exclusivity for designated orphan indications. This lowers development cost per rare-disease asset, increasing the number of siRNA and ASO candidates reaching Phase 3. Ionis's Tegsedi (inotersen), approved in 2018 for hereditary transthyretin amyloidosis, and Sarepta's Exondys 51 for Duchenne muscular dystrophy show how exclusivity protects revenue.

The Inflation Reduction Act of 2022 caps Medicare Part D out-of-pocket spending at USD 2,000 per beneficiary from 2025, removing a major adherence barrier for chronic RNA therapies such as Amvuttra. Project NextGen, administered by BARDA within the Department of Health and Human Services with USD 5 billion in funding, finances next-generation mRNA and mucosal vaccine platforms, creating procurement pull for lipid nanoparticle manufacturers. Together these mechanisms raise patient volume and underwrite manufacturing capacity that commercial sponsors would otherwise build alone.

Regulatory Barriers and Compliance Costs

PDUFA VII, covering fiscal years 2023 to 2027, sets a ten-month standard review for new molecular entities after a 60-day filing period, extending total time to decision to roughly twelve months. Both CDER and CBER require Chemistry, Manufacturing and Controls data meeting 21 CFR Parts 210 and 211 current good manufacturing practice. Lipid nanoparticle formulation and oligonucleotide synthesis each demand process validation that adds months to filing, with pre-license FDA inspections adding further delay.

The Medicare Drug Price Negotiation Program, established by Section 11001 of the Inflation Reduction Act and administered by the Centers for Medicare and Medicaid Services (CMS), sets maximum fair prices for selected drugs. Oligonucleotides approved under NDAs face negotiation after nine years of market availability, against thirteen years for biologics, which compresses the exclusivity window for siRNA franchises. Sponsors must also absorb Part D inflation rebates, which CMS calculates quarterly for drugs whose prices rise faster than the consumer price index.

Policy-Created Opportunities in the U.S.

BARDA's pandemic preparedness procurement, authorized under Section 319L of the Public Health Service Act, creates a standing government buyer for rapid-response mRNA platforms. Manufacturers with validated lipid nanoparticle capacity, including Moderna at its Norwood, Massachusetts facility, can compete for multiyear procurement contracts insulated from seasonal vaccine demand. Platform technology designation under the Food and Drug Omnibus Reform Act of 2022 extends this advantage by letting sponsors leverage data across products built on the same platform.

The Orphan Drug Act and FDA rare disease designations open a second opportunity in siRNA therapies for cardiometabolic disease. Novartis's Leqvio (inclisiran), approved in December 2021 for LDL cholesterol lowering, requires only two administrations per year after loading, reducing adherence burden under Medicare coverage. Developers targeting cardiometabolic indications with twice-yearly dosing can secure formulary positions faster than daily oral competitors, particularly in payer systems prioritizing low-cost lipid management.

Market at a Glance

Leading Market Participants

• Alnylam Pharmaceuticals
• Ionis Pharmaceuticals
• Moderna
• Pfizer
• Arrowhead Pharmaceuticals
• Sarepta Therapeutics
• Novartis
• Arbutus Biopharma
• Novo Nordisk
• Wave Life Sciences

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Chapter 9), which governs siRNA and ASO medicines approved as NDAs, and Section 351 of the Public Health Service Act, which governs mRNA products licensed as biologics under the Biologics Price Competition and Innovation Act of 2009. The FDA administers both through CDER and CBER. Key compliance requirements include Investigational New Drug submissions under 21 CFR Part 312, biologics license applications under 21 CFR Part 601, and product traceability under the Drug Supply Chain Security Act of 2013, whose full interoperability deadline took effect on 27 November 2024. Lipid and solvent waste falls under the Resource Conservation and Recovery Act, enforced by the EPA and state environmental agencies.

CMS must publish its third negotiation selection list by 1 February 2026 for prices effective in 2028, bringing Part B infused RNA therapies within negotiation scope for the first time. PDUFA VIII must be enacted before PDUFA VII authority expires on 30 September 2027. Compared with regional peers, the U.S. grants seven years of orphan market exclusivity, against ten years under European Union Regulation (EC) No 141/2000, but imposes Medicare price negotiation that has no equivalent in the EU centralized procedure under Regulation (EC) No 726/2004.

Long-Term Policy Outlook for U.S. RNA Therapeutics

By 2032, Medicare negotiation will have cycled through multiple selection rounds covering Part B drugs, compressing net prices for mature infused RNA products. Orphan exemptions enacted in July 2025 within the One Big Beautiful Bill Act will steer sponsors toward multi-indication rare disease programs that fall outside negotiation thresholds. Sponsors that structure portfolios around these exemptions will hold stronger pricing positions through the decade.

PDUFA VIII is expected to address review timelines for platform and individualized therapies, building on the platform technology designation created by the Food and Drug Omnibus Reform Act of 2022. The rare pediatric disease priority review voucher program lapsed on 20 December 2024 and awaits reauthorization, which will determine whether sponsors recover development costs for pediatric RNA therapies. Narrowed federal recommendations for COVID-19 mRNA vaccines in 2025 reduce government demand, shifting the mRNA market toward oncology and rare disease therapeutics.